Experts share here what they take away from the Conference on Retroviruses and Opportunistic Infections (CROI) each year and ...

One of the hot topics at this year's Conference on Retroviruses and Opportunistic Infections will be long COVID: potential ...

Injections of semaglutide were associated with significant improvement in cognitive function in people living with HIV (PWH), ...

Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...

As scientists gathered at the Conference for Retroviruses and Opportunistic Infections, or CROI, for meetings that run through Wednesday, they face an uncertain future. It was evident in who was ...

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

Data from two studies suggest that a once-daily combination therapy of doravirine and islatravir was noninferior to current, ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference ...

Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on ...

Switching to long-acting ART from oral treatments was cost effective for postpartum women with HIV and improved infant ...

SAN FRANCISCO -- Providing long-acting (LA) antiretroviral therapy (ART) to breastfeeding women with HIV who face adherence ...